Racial disparity with on-treatment platelet reactivity in patients undergoing percutaneous coronary intervention

American Heart Journal

Volumn 166, Issue 2, 2013, Pages 266-272

  Pendyala, Lakshmana K ^a   Torguson, Rebecca ^a   Loh, Joshua P ^a   Devaney, Joseph M ^a   Chen, Fang ^a   Kitabata, Hironori ^a   Minha, Sa'Ar ^a   Barbash, Israel M ^a   Suddath, William O ^a   Satler, Lowell F ^a   Pichard, Augusto D ^a   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; AFRICAN AMERICAN; ALLELE; ARTICLE; COHORT ANALYSIS; DISEASE REGISTRY; FEMALE; GENOTYPE; HUMAN; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PHOSPHORYLATION; PLATELET REACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE DIFFERENCE; REAL TIME POLYMERASE CHAIN REACTION;

AFRICAN AMERICANS; AGED; ARYL HYDROCARBON HYDROXYLASES; BLOOD PLATELETS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MUTATION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLYMORPHISM, GENETIC; TICLOPIDINE;

EID: 84880919871     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.04.008     Document Type: Article

References (27)

1. I. Ben-Dor, N.S. Kleiman, and E. Lev Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy Am J Cardiol 104 2009 227 233
2. D.J. Kereiakes, and P.A. Gurbel Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention J Am Coll Cardiol Interv 1 2008 111 121 (Pubitemid 351506557)
3. R. Marcucci, A.M. Gori, and R. Paniccia Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Circulation 119 2009 237 242
4. M. Kazui, Y. Nishiya, and T. Ishizuka Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite Drug Metab Dispos 38 2010 92 99
5. P.A. Gurbel, K.P. Bliden, and B.L. Hiatt Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913 (Pubitemid 36736631)
6. T. Simon, C. Verstuyft, and M. Mary-Krause for the FAST-MI Investigators. Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
7. D. Sibbing, W. Koch, and D. Gebhard Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement Circulation 121 2010 512 518
8. A.R. Shuldiner, J.R. O'Connell, and K.P. Bliden Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
9. M.J. Price, K.R. Nayak, and C.M. Barker Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention Am J Cardiol 103 2009 1339 1343
10. M.A. Gaglia Jr., D.H. Steinberg, and T.L. Pinto Slottow Racial disparities in outcomes following percutaneous coronary intervention with drug-eluting stents Am J Cardiol 103 2009 653 658
11. J. Pradhan, T.L. Schreiber, and A. Niraj Comparison of five-year outcome in African Americans versus Caucasians following percutaneous coronary intervention Catheter Cardiovasc Interv 72 2008 36 44 (Pubitemid 352008979)
12. S.D. Collins, R. Torguson, and M.A. Gaglia Jr. Does black ethnicity influence the development of stent thrombosis in the drug-eluting stent era? Circulation 122 2010 1085 1090
13. R. Pakala, and R. Waksman Currently available methods for platelet function analysis: advantages and disadvantages Cardiovasc Revasc Med 12 2011 312 322
14. L. Bonello, U.S. Tantry, and R. Marcucci Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56 2010 919 933
15. G.W. Stone Assessment of dual antiplatelet therapy with drug-eluting stents: a large-scale, prospective, multicenter registry examining the relationship between platelet responsiveness and stent thrombosis after DES implantation (ADAPT-DES) Presented at: Transcatheter Cardiovascular Therapeutics 24th Annual Scientific Symposium; October 22-26, 2012; Miami, FL 2012
16. D.J. Angiolillo, A. Fernández-Ortiz, and E. Bernardo High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability Eur Heart J 25 2004 1903 1910 (Pubitemid 39452607)
17. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment Diabetes 54 2005 2430 2435 (Pubitemid 41134272)
18. Z. Desta, X. Zhao, and J.G. Shin Clinical significance of the cytochrome P450 2C19 genetic polymorphism Clin Pharmacokinet 41 2002 913 958 (Pubitemid 35168437)
19. C. Varenhorst, S. James, and D. Erlinge Genetic variation of cyp2c19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease Eur Heart J 30 2009 1744 1752
20. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
21. J.P. Collet, J.S. Hulot, and A. Pena Cytochrome p450 2c19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
22. H.R. Luo, R.E. Poland, and K.M. Lin Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study Clin Pharmacol Ther 80 2006 33 40 (Pubitemid 43946839)
23. D. Sibbing, J. Stegherr, and W. Latz Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention Eur Heart J 30 2009 916 922
24. J.L. Mega, T. Simon, and J.P. Collet Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis J Am Med Assoc 304 2010 1821 1830
25. J.L. Mega, W. Hochholzer, and A.L. Frelinger III Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease JAMA 306 2011 2221 2228
26. S.D. Wiviott, E. Braunwald, and C.H. McCabe TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
27. L. Wallentin, R.C. Becker, and A. Budaj PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057